Background. The latest experimental studies suggest that CD4(+) cells acquire antinociceptive properties by secreting enkephalins in mice. Objectives. To investigate the potential role of CD4(+) and CD8(+) in patient with RA. Methods. Blood samples from active seropositive RA patients (ACR/EULAR 2010 criteria), treated with Metothrexate (MTX) 10mg/week ± 5-10 mg prednisolone equivalent/day, were analyzed. We assessed whether CD4(+) and CD8(+) correlated with disease activity by DAS28 -CRP, swollen joint count (SJC), tender joint count (TJC), rheumatoid factor (RF), patient general assessment (PGA) and VAS pain. Results. The study included 20 RA patients, mean age±SD 49,2±11,7yr, 90% females, mean disease duration±SD 8,8±7,3 yr. VAS and the DAS28-CRP ±SD were 55,4±25,0 and 4,8±2,8, respectively. We established a negative moderate correlation between the level of circulating CD(4+) with CD(8+), r=-0,53, p=0,015. It was found no significant correlation between CD4(+) or CD8(+) and DAS28-CRP, SJC, TJC, CRP or RF titer (r= -0,1 to 0,35; p>0,05). Meantime, it was observed a negative moderate correlation between CD4(+) and VAS pain, r= -5,34, p=0,015. Conclusions. Our observations suggest that CD4(+) and CD8(+) T-cells might have an antagonist effect in patients with RA. It was established a moderate negative correlation between CD4(+) and VAS pain, suggesting their implication in pain mechanisms.